Expert Review of Pharmacoeconomics and Outcomes Research

Interchangeability of off-patent medicines: a pharmacoeconomic perspective
pp. 519-521(3)
Author: Simoens, Steven

News in brief
pp. 523-527(5)

Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants
pp. 529-538(10)
Author: Resch, Bernhard

The cost of future problem drug use associated with young people's behaviors and circumstances
pp. 539-547(9)
Author: Marsh, Kevin

The cost of future problem drug use associated with young people's behaviors and circumstances
pp. 539-547(9)
Author: Marsh, Kevin

Generic olanzapine: health authority opportunity or nightmare?
pp. 549-555(7)
Authors: Araszkiewicz, A Aleksander; Szabert, Katarzyna; Godman, Brian; Wladysiuk, Magdalena; Barbui, Corrado; Haycox, Alan

The invisible hands made visible: recognizing the value of informal care in healthcare decision-making
pp. 557-561(5)
Authors: van Exel, Job; Bobinac, Ana; Koopmanschap, Marc; Brouwer, Werner

Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness
pp. 563-573(11)
Author: Plans, Pedro

Willingness to pay for a QALY: past, present and future
pp. 575-582(8)
Authors: Mason, Helen; Baker, Rachel; Donaldson, Cam

Employer-provided health insurance and the incidence of job lock: a literature review and empirical test
pp. 583-591(9)
Authors: Rashad, Inas; Sarpong, Eric

Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative
pp. 593-617(25)
Authors: Carter, Rob; Vos, Theo; Moodie, Marj; Haby, Michelle; Magnus, Anne; Mihalopoulos, Cathrine

Acknowledgements
pp. 623-623(1)